Bright Minds Biosciences Inc. announced positive Phase 2 results for BMB-101, showing significant anti-seizure benefits in patients with Absence Seizures and Developmental and Encephalopathic Epilepsies. The study demonstrated a median reduction of 73.1% in absence seizures and 63.3% in major motor seizures, with improved REM sleep. The company is preparing for global registrational trials and will hold a conference call today at 8AM ET to discuss the findings. BMB-101 is a novel 5-HT2C biased agonist designed for chronic treatment of neurological disorders. Preliminary data indicates safety and tolerability, with plans for further clinical development in epilepsy and other disorders.

Read more at GlobeNewswire: Bright Minds Biosciences Announces Positive Topline Results